Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ispinesib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 known ✓ | P52732 | 16/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.67 |
| ▸ | PDE6D | O43924 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ispinesib SCHEMBL15810599 | 1.00 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL29375933 | 1.00 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL3582165 | 1.00 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL2963210 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| Ispinesib SCHEMBL29711229 | 0.96 | KIF11 (1.00) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6360968 | 0.93 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6349230 | 0.93 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL14264772 | 0.93 | KIF11 (0.87) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL6351736 | 0.92 | KIF11 (0.85) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 | |
| SCHEMBL17322993 | 0.92 | KIF11 (0.84) | KIF11MAP1LC3BKCNH2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746354-B2 | Homology dependent repair genome editing | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2023-09-05 | — | — | US | claimed |
| US-20220170034-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | INARI AGRICULTURE TECHNOLOGY, INC. | 2022-06-02 | — | — | US | claimed |
| EP-3999103-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | Inari Agriculture, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| US-11331272-B2 | Hyperstabilized liposomes increase targeting of mitotic cells | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2022-05-17 | — | — | US | claimed |
| WO-2021016043-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | INARI AGRICULTURE, INC. (US) | 2021-01-28 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2026-04-02 | — | — | US | disclosed |
| CN-119345207-A | Application of composition containing Is Ping Si in preparation of anti-prostate cancer drugs | 汕头大学医学院 | 2025-01-24 | — | — | CN | disclosed |
| CN-117298279-A | Application of nitrogen-containing heterocyclic compound targeting novel coronal main protease in preparation of anti-novel coronavirus drugs | 中山大学 | 2023-12-29 | — | — | CN | disclosed |
| US-11746354-B2 | Homology dependent repair genome editing | INARI AGRICULTURE TECHNOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2022-12-29 | — | — | US | disclosed |
| US-20220249433-A1 | COMPOUND FOR TREATING NEURODEGENERATIVE DISORDERS | FUDAN UNIVERSITY (CN) | 2022-08-11 | — | — | US | disclosed |
| US-7230000-B1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INCORPORATED (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230000-B1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INCORPORATED (US) | 2007-06-12 | — | — | US | disclosed |
| US-7161002-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060193772-A1 | Drugs for treating cancer | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CANCER CENTER (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1671647-A1 | MEDICAMENT FOR TREATING CANCER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-7009049-B2 | Syntheses of quinazolinones | CYTOKINETICS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20060041130-A1 | Syntheses of quinazolinones | CYTOKINETICS, INC. AND SMITHKLINE BEECHAM CORP. | 2006-02-23 | — | — | US | disclosed |
| US-20040067969-A1 | Syntheses of quinazolinones | CYTOKINETICS, INCORPORATED | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067969-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885MAP1LC3B 544/4885KCNH2 941/4885 |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | HDAC6, HDAC3, CHKA | KIF11 743/4885MAP1LC3B 1101/4885KCNH2 2608/4885 |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | PLK1, BID, ABCB1 | KIF11 244/4885MAP1LC3B 609/4885KCNH2 2809/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | KIF11 3522/4885MAP1LC3B 973/4885KCNH2 1639/4885 |
| US-20220249433-A1 | COMPOUND FOR TREATING NEURODEGENERATIVE DISORDERS | HTT, MAPT, SNCA | KIF11 266/4885MAP1LC3B 70/4885KCNH2 3624/4885 |
| US-20060041130-A1 | Syntheses of quinazolinones | NDUFS3, NDUFS2, NQO2 | KIF11 1865/4885MAP1LC3B 544/4885KCNH2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.